What was the overall market valuation for migraine drugs in Italy in 2024?

The overall market valuation for migraine drugs in Italy was $197.02 Million in 2024. Read More

What is the projected market valuation for migraine drugs in Italy by 2035?

The projected market valuation for migraine drugs in Italy is $314.77 Million by 2035. Read More

What is the expected CAGR for the Italy migraine drugs market during the forecast period 2025 - 2035?

The expected CAGR for the Italy migraine drugs market during the forecast period 2025 - 2035 is 4.35%. Read More

Which companies are key players in the Italy migraine drugs market?

Key players in the Italy migraine drugs market include Amgen, Eli Lilly, Teva Pharmaceutical Industries, Pfizer, Boehringer Ingelheim, Novartis, AbbVie, AstraZeneca, and GlaxoSmithKline. Read More

What were the valuations for abortive and preventive drugs in the Italy migraine drugs market?

In 2024, the valuations for abortive drugs ranged from $40.0 Million to $60.0 Million, while preventive drugs ranged from $50.0 Million to $80.0 Million. Read More

How do the valuations for different routes of administration compare in the Italy migraine drugs market?

The valuations for oral administration were between $80.0 Million and $130.0 Million, injectable routes ranged from $60.0 Million to $90.0 Million, and nasal routes were between $57.02 Million and $94.77 Million. Read More

What are the therapeutic classes represented in the Italy migraine drugs market?

The therapeutic classes in the Italy migraine drugs market include NSAIDs, Ergots, Beta Blockers, and Antidepressants, with valuations ranging from $30.0 Million to $129.77 Million. Read More

What is the market valuation for migraine drugs among different patient demographics in Italy?

In 2024, the market valuation for adults was between $118.51 Million and $183.12 Million, while for children and geriatrics, it ranged from $39.02 Million to $70.18 Million. Read More

What trends are observed in the use of CGRP inhibitors in the Italy migraine drugs market?

CGRP inhibitors had valuations ranging from $30.0 Million to $50.0 Million in 2024, indicating a growing interest in this class of drugs. Read More

How does the market for triptans compare to other migraine drug segments in Italy?

The market for triptans was valued between $77.02 Million and $124.77 Million in 2024, suggesting a strong position relative to other segments. Read More

Italy Migraine Drugs Market

Italy Migraine Drugs Market Research Report: Size, Share, Trend Analysis By End-User (Hospitals And Clinics, Retail Pharmacy, Online Pharmacy, Others), By Types (Episodic Migraine, Chronic Migraine), By Treatment Type (Acute, Preventive, Neuromodulation Devices) and By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

4.35%

2024 Market Size

$ 197.02 Million

2035 Market Size

$ 314.77 Million

Medical Device ● Updated February 2026 Report ID: MRFR/MED/49257-HCR | Pages: 200 | Author: Nidhi Mandole, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Type (USD Million)
  1. 4.1.1 Abortive Drugs
  2. 4.1.2 Preventive Drugs
  3. 4.1.3 CGRP Inhibitors
  4. 4.1.4 Triptans
2. 4.2 Construction, BY Route of Administration (USD Million)
  1. 4.2.1 Oral
  2. 4.2.2 Injectable
  3. 4.2.3 Nasal
3. 4.3 Construction, BY Therapeutic Class (USD Million)
  1. 4.3.1 NSAIDs
  2. 4.3.2 Ergots
  3. 4.3.3 Beta Blockers
  4. 4.3.4 Antidepressants
4. 4.4 Construction, BY Patient Demographics (USD Million)
  1. 4.4.1 Adults
  2. 4.4.2 Children
  3. 4.4.3 Geriatrics
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Amgen (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Eli Lilly (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Teva Pharmaceutical Industries (IL)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Pfizer (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Boehringer Ingelheim (DE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AbbVie (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AstraZeneca (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 GlaxoSmithKline (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 ITALY MARKET ANALYSIS BY TYPE
3. 6.3 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 ITALY MARKET ANALYSIS BY THERAPEUTIC CLASS
5. 6.5 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
16. 6.16 CONSTRUCTION, BY THERAPEUTIC CLASS, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY THERAPEUTIC CLASS, 2024 TO 2035 (USD Million)
18. 6.18 CONSTRUCTION, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.2.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Million)
  4. 7.2.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Italy Migraine Drugs Market Segmentation

Italy Migraine Drugs Market By Type (USD Million, 2025-2035)

Abortive Drugs
Preventive Drugs
CGRP Inhibitors
Triptans

Italy Migraine Drugs Market By Route of Administration (USD Million, 2025-2035)

Oral
Injectable
Nasal

Italy Migraine Drugs Market By Therapeutic Class (USD Million, 2025-2035)

NSAIDs
Ergots
Beta Blockers
Antidepressants

Italy Migraine Drugs Market By Patient Demographics (USD Million, 2025-2035)

Adults
Children
Geriatrics

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”